-

BostonGene to Showcase Integrated Approach to Precision Medicine at PEGS Boston 2023

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene announced today that as part of its ongoing commitment to improving the diagnosis and personalized treatment recommendations for cancer patients, it will participate in and present at PEGS Boston Summit on May 15 – 19, 2023, at the Hynes Convention Center. The event is the leading biologics event covering all aspects of biologic drug development with in-depth presentations on protein and antibody engineering, immunotherapy, oncology, expression, analytics, immunogenicity, and more. BostonGene will also exhibit at booth #228.

BostonGene session details can be found below:

Comprehensive genomic and immune profiling of tumor tissue and peripheral blood to predict immunotherapy response and identify mechanisms of immune escape

  • Monday, May 15 | 2:50 PM ET
  • Speaker: Michael Goldberg, PhD, Director of Immunology, BostonGene

The session will address how BostonGene’s innovative AI and ML-based solutions can precisely predict immunotherapy responses, resistance, and immune-related adverse events. The presentation will underscore how our comprehensive genomic and immune profiling platform will assist in providing patients with the most effective treatments and mechanistic stratification that will propel bringing novel agents and combinations into the clinic and ultimately accelerate the next phase of drug discovery.

To learn more, or to schedule a meeting with BostonGene during PEGS Boston 2023, please contact Maria Proia at maria.proia@bostongene.com.

About BostonGene Corporation

BostonGene’s mission is to power healthcare’s transition to personalized medicine using our AI-based molecular and immune profiling to improve the standard of care, accelerate research, and reduce overall cost of cancer care. BostonGene’s tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at http://www.BostonGene.com.

Contacts

Media:
BostonGene
Erin O’Reilly
+1-617-283-2285
Erin.Oreilly@BostonGene.com

BostonGene Corporation


Release Versions

Contacts

Media:
BostonGene
Erin O’Reilly
+1-617-283-2285
Erin.Oreilly@BostonGene.com

Social Media Profiles
More News From BostonGene Corporation

BostonGene to Present Multimodal AI Advances in Tumor-of-Origin Classification and Tumor Microenvironment Profiling at the ESMO AI & Digital Oncology Congress 2026

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of an AI model for tumor and immune biology, today announced its participation in ESMO AI & Digital Oncology Congress 2026 taking place November 16–18, 2026 in Berlin, Germany. The international forum unites oncologists, data scientists, and industry leaders to showcase advances in AI and computational biology across cancer care. BostonGene will demonstrate how its multimodal AI platform addresses critical oncology challenges, including...

BostonGene Showcases Biologically Grounded AI at ACR Convergence 2026 to Advance Precision Rheumatology and Autoimmune Disease Stratification

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of an AI model for tumor and immune biology, announced today that it will present new data demonstrating the application of its biologically grounded AI in non-oncology indications at the American College of Rheumatology (ACR) Convergence 2026. ACR Convergence 2026, the world's premier rheumatology event, will be held November 6–11 at the Orange County Convention Center in Orlando, Florida. BostonGene combines multimodal profiling with biol...

BostonGene Wins Three Gold Stevie® Awards

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of an AI model for tumor and immune biology, today announced that it has been awarded three Gold Stevie® Awards in the 2026 Stevie® Awards for Technology Excellence, taking top honors as Company of the Year, New Product of the Year, and Technology Breakthrough of the Year in Biotechnology. The awards recognize a fundamental shift in how oncology drugs are developed. Traditional AI approaches in drug development often rely on retrospective a...
Back to Newsroom